Clinical Trials for Hepatobiliary and Pancreatic Cancer Diagnosis and Treatment (2nd Edition)

Dear Colleagues,

This Special Issue is the second edition of a previous issue on the topic of “Clinical Trials for Hepatobiliary and Pancreatic Cancer Diagnosis and Treatment” (https://www.mdpi.com/journal/cancers/special_issues/G4GPO2HF1N).

Hepatobiliary and pancreatic cancer remain among the most challenging malignancies to treat. Of all the modalities available for the treatment of hepatobiliary and pancreatic cancer, only a few treatment modalities, including resection and ablation therapy, offer an opportunity to cure these conditions. However, in the majority of patients with hepatobiliary and pancreatic cancer, the cancer is already at an advanced and unresectable stage at the time of diagnosis. Even among patients with a curable disease, the long-term outcomes remain unsatisfactory, with 5-year survival rates remaining at a dismal level of around 50% or below, owing to the high rate of recurrence even after treatment with a curative intent. Hence, novel clinical studies are needed to improve diagnostic and therapeutic strategies over the next decade.

This Special Issue will discuss recent and ongoing clinical trials to establish a better diagnostic method enabling the detection of these types of cancer at an earlier stage, to establish effective surgical or non-surgical treatments for patients with localized or systemic disease, and to improve the quality of life of patients with life-threatening diseases at any stage.

Dr. Takuji Okusaka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.